Malaria: Opportunity Analysis and Forecasts to 2027

2018-11-24
Price :
Published : Nov-2018
No. of Pages : 164

Malaria: Opportunity Analysis and Forecasts to 2027

Summary

Malaria is a potentially life-threatening disease caused by Plasmodium parasites, which are transmitted to humans through the bites of infected female Anopheles spp mosquitoes. For over 2,500 years, fevers, a hallmark symptom of malaria, were attributed to miasmas (foul stenches or vapors) rising from nearby swamps. Scientific studies of malaria became possible only after Charles Louis Alphonse Laveran’s discovery of the causative parasite in 1880 and the subsequent incrimination of mosquitoes as the vectors-first for avian malaria by Ronald Ross in 1897, and then for human malaria by the Italian scientist Grassi and his colleagues-between 1898 and 1900.

Although the disease is preventable and curable if promptly treated, in 2016 there were 216,000,000 annual cases of malaria in 91 countries, along with 445,000 deaths associated with malaria, according to the World Health Organization (WHO). These mortality number represent a notable improvement from 2000, when malaria mortality statistics were documented at up to 1,000,000 deaths annually.

This report will provide an opportunity and forecast assessment on the six pharmaceutical markets (6M) representing areas with the largest disease burden for malaria. The countries specifically included in this report are the Democratic Republic of the Congo (DRC), Ghana, India, Indonesia, Kenya, and Nigeria.

Key Questions Answered

– How will the malaria market landscape in the 6M (DRC, Ghana, Kenya, Nigeria, India, Indonesia) change from 2017-2027?
– What are the most promising late-stage pipeline products for malaria?
– How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing treatment and prevention options?
– What are the remaining unmet needs in the malaria space?
– What drivers and barriers will affect malaria product sales in the 6M?

Scope

– Overview of malaria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
– Topline malaria market revenue from 2017-2027. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
– Key topics covered include current treatment and prophylactic options, unmet needs and opportunities, and the drivers and barriers affecting malaria product sales in the 6M.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global malaria space. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global malaria market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the malaria market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products Summary An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening. Despite this high disease burden, treatment options are limited for many conditions and patients often recei......
$6995

Digital Therapeutics and Their Impact on Healthcare

Digital Therapeutics and Their Impact on Healthcare Summary Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions. This report provides an overview of cur......
$7995

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends – Q1 2019

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019 Summary GlobalData's "Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information o......
$1500

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Italy

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Italy. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Italy. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Diabetic Foot Ulcers Global Clinical Trials Review, H1, 2019

Diabetic Foot Ulcers Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diabetic Foot Ulcers Global Clinical Trials Review, H1, 2019" provides an overview of Diabetic Foot Ulcers clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Foot Ulcers. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Dyspareunia Global Clinical Trials Review, H1, 2019

Dyspareunia Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dyspareunia Global Clinical Trials Review, H1, 2019" provides an overview of Dyspareunia clinical trials scenario. This report provides top line data relating to the clinical trials on Dyspareunia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Diffuse Diabetic Macular Edema Global Clinical Trials Review, H1, 2019

Diffuse Diabetic Macular Edema Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diffuse Diabetic Macular Edema Global Clinical Trials Review, H1, 2019" provides an overview of Diffuse Diabetic Macular Edema clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Diabetic Macular Edema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's pro......
$2500

Empyema Global Clinical Trials Review, H1, 2019

Empyema Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Empyema Global Clinical Trials Review, H1, 2019" provides an overview of Empyema clinical trials scenario. This report provides top line data relating to the clinical trials on Empyema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated fro......
$2500

Dental Caries Global Clinical Trials Review, H1, 2019

Dental Caries Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dental Caries Global Clinical Trials Review, H1, 2019" provides an overview of Dental Caries clinical trials scenario. This report provides top line data relating to the clinical trials on Dental Caries. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy